Can charcoal improve outcomes in COVID-19 infections?

Zeid J. Khitan  
*Marshall University*, zkhitan@marshall.edu

Imran Khawaja  
*Marshall University*

Maurice A. Mufson  
*Marshall University*, mufson@marshall.edu

Juan R. Sanabria  
*Marshall University*, sanabriaj@marshall.edu

Nader G. Abraham  
*Marshall University*, abrahamn@marshall.edu

*See next page for additional authors*

Follow this and additional works at: [https://mds.marshall.edu/int_med](https://mds.marshall.edu/int_med)

Part of the Internal Medicine Commons

**Recommended Citation**


This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in Internal Medicine by an authorized administrator of Marshall Digital Scholar. For more information, please contact zhangj@marshall.edu, beachgr@marshall.edu.
Authors
Zeid J. Khitan, Imran Khawaja, Maurice A. Mufson, Juan R. Sanabria, Nader G. Abraham, Stephen J. Peterson, Uma Sundaram, and Joseph I. Shapiro

This article is available at Marshall Digital Scholar: https://mds.marshall.edu/int_med/68
Can charcoal improve outcomes in COVID-19 infections?

Zeid J. Khitan\textsuperscript{a}, Imran Khawaja\textsuperscript{a}, Maurice A. Mufson\textsuperscript{a}, Juan R. Sanabria\textsuperscript{a}, Nader G. Abraham\textsuperscript{b}, Stephen J. Peterson\textsuperscript{c}, Uma Sundaram\textsuperscript{a}, Joseph I. Shapiro\textsuperscript{a,⁎}

\textsuperscript{a} Joan C. Edwards School of Medicine, Marshall University, United States
\textsuperscript{b} New York Medical College, Touro University, United States
\textsuperscript{c} New York Presbyterian Brooklyn Methodist Hospital/Weill Cornell Medicine, United States

A B S T R A C T

COVID-19 infection causes considerable morbidity and mortality, especially to those who are aged, have impaired renal function and are obese. We propose to examine the potential utility of oral activated charcoal with the hypothesis that such treatment would lower absorption of microbiome derived toxins and ameliorate systemic oxidant stress and inflammation.

Background to hypothesis

While coronaviruses have been known to cause potentially serious disease for ½ a century [1], COVID-19 has created a pandemic with adverse health consequences beyond the experiences of those people living today. As of July 14, 2020, approximately 13 million people have been infected with at least 570,000 dying from this disease and its complications [2]. Interestingly, the range of signs and symptoms ranges from those who have essentially no symptoms to those with fatal disease. It appears that age, renal dysfunction and obesity are amongst the most important risk factors for serious or fatal COVID-19 infection [3,4]. While there are multiple mechanisms by which this virus can injure hosts, it appears that increases in systemic cytokines and widespread inflammation may play an important role [5].

Our research group has focused on the role that adipocytes play in the pathophysiology of metabolic and CV disease. In particular, we have noted that in experimental models of these diseases, the redox state within adipocytes has profound consequences to systemic oxidant stress, inflammation and disease phenotype [6–9]. We have specifically identified that products derived from tyrosine and tryptophan which are produced by the intestinal microbiome, specifically p-cresyl sulfate and indoxyl sulfate can directly cause oxidant stress in adipocytes [10]. These substances are excreted by the kidney and are known to accumulate in the plasma with impaired renal function [11]. Some workers have hypothesized that the symptoms of uremia itself can be modulated by use of oral activated charcoal to lower absorption of these microbiome products [12]. Experimental data also support the concept that uremia potentiates sepsis and that oral activate charcoal can attenuate this [13].

On this background, the adipocyte is a known target for the virus [14], and as people age there are statistically likely decreases in renal function and increases in visceral adiposity [15]. There are data suggesting that the virus can induce oxidative stress in adipocytes [16] and this oxidative stress can upregulate the expression of the ACE-2 protein [17], the putative receptor for COVID-19. In short, the elderly likely have increases in the circulating concentrations of these potentially toxic substances as well as the adipocyte mass which responds to them [16].

Hypothesis

Administration of activated charcoal has been shown to be well tolerated when administered to a patients with renal dysfunction [18,19]. This activated charcoal has also been shown to effectively decrease circulating levels of p-cresyl sulfate and indoxyl sulfate [13]. In addition to its ability to scavenge these microbiome derived toxins, activated charcoal may also have non-specific absorptive properties that blunt inflammatory responses to [20] or possibly inactivate viruses [21]. Certainly, COVID-19 infection may directly involve the gastrointestinal tract in both human and bat [22]. Given that the potential toxicity of oral activated charcoal is so limited, we propose that an investigation of this coal-derived substance, widely available in the “mountain” state of WV, to potentially attenuate these adverse outcomes be explored as definitive work seeking effective antivirals and development of a vaccine continues. A schematic summarizing this hypothesis is shown in Fig. 1.

To test this hypothesis, we would suggest first a proof of concept study where a relatively small group of patients at high risk for COVID-19 complications are given activated charcoal at doses similar to that used in previous renal failure studies [18,19] when the diagnosis is first made. Cytokine levels, concentrations of indoxyl sulfate and p-cresyl sulfate along with evidence for systemic oxidant stress (e.g., protein

⁎ Corresponding author at: Joan C. Edwards School of Medicine, 1600 Medical Center Drive, Suite 3408, Dean’s Office, Huntington, WV 25701, United States. E-mail address: shapiroj@marshall.edu (J.I. Shapiro).

https://doi.org/10.1016/j.mehy.2020.110176
Received 29 July 2020; Accepted 9 August 2020
Available online 10 August 2020
0306-9877/ © 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
carbonylation) and inflammation would be serially monitored. Should preliminary outcomes be improved with this strategy, a randomized, prospective blinded study should be performed prior to large scale adaptation of this treatment strategy.

Contributions
JIS: Put forward the central hypothesis.
ZJK, IK, MAM, JRS, NGA, SVP, US, JIS: Participated in drafting and finalizing the paper and in literature search.

Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments
This work was supported by National Institutes of Health grants HL109015, HL071556 and HL105649 (to JIS), and the BrickStreet Foundation and the Huntington Foundation, Inc. (to JIS).

References